Cornercap Investment Counsel Inc. Takes Position in Emergent BioSolutions Inc. (NYSE:EBS)

Cornercap Investment Counsel Inc. acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,020 shares of the biopharmaceutical company’s stock, valued at approximately $115,000.

Other institutional investors have also recently added to or reduced their stakes in the company. LPL Financial LLC grew its stake in Emergent BioSolutions by 34.5% in the 4th quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 3,875 shares during the period. American Century Companies Inc. boosted its holdings in shares of Emergent BioSolutions by 23.4% during the fourth quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock worth $20,437,000 after purchasing an additional 404,667 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Emergent BioSolutions by 8.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 902,332 shares of the biopharmaceutical company’s stock worth $8,626,000 after purchasing an additional 69,157 shares during the last quarter. Prescott Group Capital Management L.L.C. grew its position in shares of Emergent BioSolutions by 250.0% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $2,008,000 after purchasing an additional 150,000 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new position in Emergent BioSolutions in the fourth quarter valued at $98,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on EBS shares. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Friday, March 21st. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Price Performance

Shares of Emergent BioSolutions stock opened at $4.68 on Monday. The business’s fifty day moving average price is $8.04 and its 200 day moving average price is $8.65. Emergent BioSolutions Inc. has a twelve month low of $1.82 and a twelve month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $254.03 million, a P/E ratio of -1.14 and a beta of 1.80.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.40. The business had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the previous year, the company posted ($0.77) EPS. As a group, research analysts anticipate that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Insiders Place Their Bets

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at $589,413. The trade was a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.20% of the stock is owned by insiders.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.